TransMedics [TMDX] vs Bio-Rad Laboratories [BIO] Detailed Stock Comparison

TransMedics Group Inc.

NASDAQ
Loading...

Bio-Rad Laboratories Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: TransMedics Group Inc. wins in 7 metrics, Bio-Rad Laboratories Inc. wins in 13 metrics, with 0 ties. Bio-Rad Laboratories Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric TransMedics Group Inc. Bio-Rad Laboratories Inc. Better
P/E Ratio (TTM) 23.29 10.98 Bio-Rad Laboratories Inc.
Price-to-Book Ratio 8.22 1.11 Bio-Rad Laboratories Inc.
Debt-to-Equity Ratio 109.76 18.58 Bio-Rad Laboratories Inc.
PEG Ratio 0.02 -0.05 TransMedics Group Inc.
EV/EBITDA 28.01 18.75 Bio-Rad Laboratories Inc.
Profit Margin (TTM) 31.43% 29.42% TransMedics Group Inc.
Operating Margin (TTM) 13.23% 8.87% TransMedics Group Inc.
EBITDA Margin (TTM) 13.23% 8.87% TransMedics Group Inc.
Return on Equity 54.24% 10.84% TransMedics Group Inc.
Return on Assets (TTM) 7.25% 1.67% TransMedics Group Inc.
Free Cash Flow (TTM) $133.59M $374.60M Bio-Rad Laboratories Inc.
1-Year Return -48.97% 26.01% Bio-Rad Laboratories Inc.
Price-to-Sales Ratio (TTM) 6.47 3.20 Bio-Rad Laboratories Inc.
Enterprise Value $3.77B $8.09B Bio-Rad Laboratories Inc.
EV/Revenue Ratio 6.22 3.13 Bio-Rad Laboratories Inc.
Gross Profit Margin (TTM) 58.11% 49.80% TransMedics Group Inc.
Revenue per Share (TTM) $18 $95 Bio-Rad Laboratories Inc.
Earnings per Share (Diluted) $4.87 $27.85 Bio-Rad Laboratories Inc.
Beta (Stock Volatility) 2.08 1.16 Bio-Rad Laboratories Inc.
Short % of Float 36.27% 0.00% Bio-Rad Laboratories Inc.

TransMedics Group Inc. vs Bio-Rad Laboratories Inc. Stock Performance Analysis

Loading Price Chart...

TMDX
BIO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
TransMedics Group Inc.3.52%6.10%19.43%-39.47%-38.71%-38.48%
Bio-Rad Laboratories Inc.1.17%-0.70%16.87%10.73%-6.05%-5.24%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
TransMedics Group Inc.-48.97%-7.27%144.83%193.99%193.99%193.99%
Bio-Rad Laboratories Inc.26.01%-24.07%-54.09%102.91%143.91%328.31%

Performance & Financial Health Analysis: TransMedics Group Inc. vs Bio-Rad Laboratories Inc.

MetricTMDXBIO
Market Information
Market Cap i$3.91B$7.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i666,207239,625
90 Day Avg. Volume i896,759284,785
Last Close$75.48$289.28
52 Week Range$60.10 - $156.00$222.80 - $343.12
% from 52W High-51.62%-15.69%
All-Time High$177.37 (Aug 19, 2024)$832.70 (Aug 30, 2021)
% from All-Time High-57.44%-65.26%
Growth Metrics
Quarterly Revenue Growth0.32%0.04%
Quarterly Earnings Growth14.37%0.04%
Financial Health
Profit Margin (TTM) i0.31%0.29%
Operating Margin (TTM) i0.13%0.09%
Return on Equity (TTM) i0.54%0.11%
Debt to Equity (MRQ) i109.7618.58
Cash & Liquidity
Book Value per Share (MRQ)$13.81$276.16
Cash per Share (MRQ)$14.24$57.08
Operating Cash Flow (TTM) i$192.84M$532.20M
Levered Free Cash Flow (TTM) i$94.00M$256.55M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: TransMedics Group Inc. vs Bio-Rad Laboratories Inc.

MetricTMDX (Apr 24, 2026)BIO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i23.2910.98
Forward P/E i30.8026.94
PEG Ratio i0.02-0.05
Price to Sales (TTM) i6.473.20
Price to Book (MRQ) i8.221.11
Market Capitalization
Market Capitalization i$3.91B$7.60B
Enterprise Value i$3.77B$8.09B
Enterprise Value Metrics
Enterprise to Revenue i6.223.13
Enterprise to EBITDA i28.0118.75
Risk & Other Metrics
Beta i2.081.16
Book Value per Share (MRQ) i$13.81$276.16

Financial Statements Comparison: TransMedics Group Inc. vs Bio-Rad Laboratories Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTMDX (2025)BIO (2025)
Revenue/Sales i605.49M2.58B
Cost of Goods Sold i242.69M1.24B
COGS % of Revenue i40.1%48.1%
Gross Profit i362.81M1.34B
Gross Margin i59.9%51.9%
Research & Development i69.06M275.60M
Operating Income (EBIT) i108.58M218.60M
Operating Margin i17.9%8.5%
EBITDA i148.49M480.70M
EBITDA Margin i24.5%18.6%
Pre-Tax Income i107.52M995.50M
Pre-Tax Income % of Revenue i17.8%38.5%
Income Tax i-82.77M235.60M
Income Tax % of Revenue i-13.7%9.1%
Net Income (Profit) i190.29M759.90M
Profit Margin i31.4%29.4%

Balance Sheet & Liquidity Metrics

MetricTMDX (2025)BIO (2025)
Cash & Equivalents i488.37M529.80M
Total Current Assets i637.78M2.91B
Total Current Assets % of Revenue i105.3%112.5%
Total Current Liabilities i89.31M517.00M
Total Current Liabilities % of Revenue i14.7%20.0%
Long-Term Debt i505.97M1.35B
Long-Term Debt % of Revenue i83.6%52.2%
Total Shareholders Equity i473.10M7.45B
Retained Earnings i-277.95M8.18B
Retained Earnings % of Revenue i-45.9%316.5%
Property, Plant & Equipment i45.54M1.49B

Cash Flow Statement Comparison

MetricTMDX (2025)BIO (2025)
Operating Cash Flow i180.45M1.25B
Operating Cash Flow % of Revenue i29.8%48.4%
Capital Expenditures i-59.25M-157.50M
Free Cash Flow i133.59M374.60M
FCF Margin i22.1%14.5%
Debt Repayment iN/A-500,000
Common Stock Repurchase iN/A-295.50M

Short Interest & Institutional Ownership Analysis

MetricTMDXBIO
Shares Short i8.03M26
Short Ratio i7.660.00
Short % of Float i36.27%0.00%
Shares Outstanding i34.27M26.99M
Float Shares i33.19M21.13M
% Held by Insiders i3.30%16.20%
% Held by Institutions i110.68%91.50%
% Held by Public i-13.98%-7.70%

Dividend Analysis & Yield Comparison: TransMedics Group Inc. vs Bio-Rad Laboratories Inc.

MetricTMDXBIO
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A